Interleukin-1, interleukin-1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membrane

被引:1
|
作者
Cauli, A [1 ]
Yanni, G [1 ]
Panayi, GS [1 ]
机构
[1] UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT MED,DIV MED,RHEUMATOL UNIT,LONDON SE1 9RT,ENGLAND
来源
BRITISH JOURNAL OF RHEUMATOLOGY | 1997年 / 36卷 / 09期
关键词
rheumatoid arthritis; osteoarthritis; interleukin-1; interleukin-1 receptor antagonist; synovial membrane; immunohistochemistry; macrophages;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine whether interleukin-1 (IL-1) and interleukin-1 receptor antagonist (IL-1ra) are produced by different macrophage subsets, we applied immunoperoxidase and double-labelling immunofluorescence techniques to 10 rheumatoid arthritis (RA) and 10 osteoarthritis (OA) synovial membranes. In RA, greater numbers of early 27E10+ macrophages were found in the sublining layer while mature 25F9+ macrophages were more abundant in the lining layers. The majority of IL-1 alpha+ cells were also IL-1ra+ (79 +/- 12% sublining layer, 98 +/- 2% lining layer). In OA sublining layer, a higher percentage of cells double stained for 25F9 and IL-1ra was detected compared to those double stained for 25F9 and IL-1 alpha (P < 0.004). In OA, 25F9+ macrophages demonstrated a lower percentage of IL-1 alpha+ in the lining and sublining layers compared to RA (P < 0.02 and P < 0.004, respectively). It may be concluded that once monocytes have migrated into the RA joint, they undergo phenotypic and functional changes from an early profile (27E10+, CD14+, low percentage of IL-1+ and IL-1ra+ cells) to a mature profile (CD14+/-, 25F9+, RM3/1+, high percentage of IL-1+ and IL-1ra+ cells).
引用
下载
收藏
页码:935 / 940
页数:6
相关论文
共 50 条
  • [41] Interleukin-1 β and interleukin receptor antagonist gene polymorphisms:: Relationship to occurrence and severity of rheumatoid arthritis
    Navaux, F
    Lescoulie, PL
    Constantin, A
    Mazières, B
    Cantagrel, A
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S64 - S64
  • [42] INTERLEUKIN-1 RECEPTOR ANTAGONIST COMPETITIVELY INHIBITS THE BINDING OF INTERLEUKIN-1 TO THE TYPE-II INTERLEUKIN-1 RECEPTOR
    GRANOWITZ, EV
    MANCILLA, J
    CLARK, BD
    DINARELLO, CA
    CLINICAL RESEARCH, 1991, 39 (02): : A462 - A462
  • [43] Interleukin-1 receptor antagonist gene therapy for arthritis
    Krishnan, BR
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 1999, 1 (04) : 454 - 457
  • [44] The effects of treatment with interleukin-1 receptor antagonist (IL-1RA) on the synovial membrane and joints of patients with rheumatoid arthritis.
    Cunnane, G
    Cassidy, N
    Madigan, A
    Murphy, E
    FitzGerald, O
    Bresnihan, B
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S138 - S138
  • [45] Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist
    Arend, WP
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 30 (05) : 1 - 6
  • [46] Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis
    Barrera, P
    van der Laken, CJ
    Boerman, OC
    Oyen, WJG
    van de Ven, MTP
    van Lent, PLEM
    van de Putte, LBA
    Corstens, FHM
    RHEUMATOLOGY, 2000, 39 (08) : 870 - 874
  • [47] The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    Bresnihan, B
    BIODRUGS, 2001, 15 (02) : 87 - 97
  • [48] Treatment of patients with rheumatoid arthritis with the interleukin-1 receptor antagonist anakinra (Kineret®)
    Rubbert-Roth, A
    Perniok, A
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2003, 62 (04): : 367 - 377
  • [49] INTERLEUKIN-1 RECEPTOR ANTAGONIST: RELATION TO CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Almeida, C.
    Quevedo-Abeledo, J. C.
    Caceres Martin, L.
    Hernandez Hernandez, V.
    Delgado-Gonzalez, A.
    Ferraz-Amaro, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1166 - 1166
  • [50] The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist
    Barry Bresnihan
    BioDrugs, 2001, 15 : 87 - 97